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Abstract 
Background: Incorrect insulin prescription 
and administration has been associated with 
substantial medication-related patient harm and 
mortality. We aimed to assess whether blood 
glucose was being monitored according to our local 
hospital protocol and whether insulin was being 
prescribed accurately by doctors and administered 
safely by nurses. Moreover, we evaluated whether 
education to nurses and doctors resulted in less 
insulin prescription and administration errors.  
Methods: Inpatients on insulin in Mater Dei 
Hospital’s medical wards were recruited. Data was 
collected from patients’ files on errors in insulin 
prescription and on the timing of blood glucose 
monitoring and insulin administration in relation to 
meals. The first audit was carried out in 2013. A re-
audit was carried out in 2017 following education to 
doctors and nurses and a change in the treatment 
chart format. The z-test was used to compare the 
two audits. 
Results: On re-auditing, a significant 
improvement was noted in the timing of blood 
glucose monitoring and insulin administration in 
relation to meals, in the legibility of the insulin 
doses, ‘Units’ were more written in full and 
supplementary Actrapid® was more frequently 
prescribed where indicated. However, inappropriate 
omission of fixed insulin doses occurred more 
often, while written instructions by doctors on when 
to administer fixed insulin, including supplementary 
Actrapid®, were still lacking. Moreover, there was 
no improvement in adherence to the supplementary 
Actrapid® algorithm by nurses. 
Conclusion: Further education and an 
improved treatment chart including hypo- and 
hyperglycaemia trouble-shooting guidelines are 
required to further reduce insulin prescription and 
administration errors. 
Key words 
insulin; prescription errors; administration 
errors; blood glucose monitoring; education. 
Introduction 
Subcutaneous insulin is considered a high-
alert inpatient medication by the Institute for Safe 
Medication Practices.1 It has a narrow therapeutic 
index and thus requires accurate dose changes 
together with careful administration and regular 
monitoring.2 In a review by Cousins et al, 16,600 
incidents related to incorrect insulin prescription 
and administration were identified between 
November 2003 and November 2009. Twenty four 
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percent of these incidents resulted in patient harm. 
These incidents mainly occurred following the 
administration of the wrong insulin type, dose, 
frequency or strength, as well as inappropriate 
omission or delayed dosage, leading to insulin 
being administered at an incorrect time in relation 
to food. Moreover, the abbreviation of ‘Units’ to 
‘U’ or ‘IU’ may be read as 0 or 10, especially in 
cases of poor handwriting, which can result in the 
administration of 10 or 100 times higher insulin 
doses.3 Confusion between the different available 
insulins or administration of insulin meant for 
another patient can also result in dangerous blood 
glucose fluctuations.4 Thus, although insulin can be 
a life-saving medication, it can also be life-
threatening when used incorrectly.5 
Insulin was reported to be implicated in 33% 
of medication error related mortality. Much of these 
insulin prescription and administration errors can be 
the result of illegible handwriting, heavy work-
loads on doctors and nurses, impaired 
communication, unawareness of the importance and 
possible complications associated with the incorrect 
timing of insulin administration in relation to meals 
and of the need to keep blood glucose controlled, as 
well as the absence of back-up checking systems.5 
According to our teaching hospital’s clinical 
practice guideline relating to insulin administration, 
all diabetic patients on insulin admitted to hospital, 
should have their capillary blood glucose checked 
30 minutes before each meal and at bedtime 
(10pm).6 This is because Actrapid®, which is the 
short-acting human insulin available at Mater Dei 
Hospital, should be administered 30 minutes prior 
to a meal or a carbohydrate containing snack.7 On 
the other hand, rapid-acting insulin analogues (such 
as Novorapid®) should be given immediately 
before or after a meal, but the dose may need to be 
adjusted according to the patient’s capillary blood 
glucose level prior to the meal.8 Basal insulins such 
as Insulatard® or long-acting insulin analogues e.g. 
insulin Glargine, do not need to be administered in 
relation to meals.9, 10 However, when Insulatard® is 
mixed with Actrapid® to form biphasic insulin or 
Mixtard®, administration should occur 30 minutes 
before a meal.11  
Our trust also has a supplementary Actrapid® 
algorithm available to nursing staff, which guides 
them in administering supplementary Actrapid® 
pre-meals and at bedtime when blood glucose 
monitoring (BGM) is greater than 8mmol/L. An 
algorithm for supplementary Actrapid® is assigned 
according to the patient’s total daily dose of insulin 
or alternatively according to the patient’s body 
weight.6 
The aim of this audit was to assess whether 
BGMs were being checked according to our local 
Mater Dei hospital protocol and whether insulin 
was being prescribed accurately by doctors and 
administered safely by nursing staff. Moreover, we 
evaluated the use of supplementary Actrapid®, and 
whether this was being given in accordance to our 
local guideline. Another objective of this audit was 
to document any inappropriate insulin omission as 
well as resultant complications secondary to 
improper insulin prescription or administration. The 
re-audit aimed to assess whether educational 
sessions to both doctors and nurses led to a 
reduction of such errors in insulin prescription and 
administration. 
Materials and Methods 
The treatment charts of adult patients aged 18 
years and over, who were admitted to any acute or 
general medical ward, were reviewed for possible 
inclusion in the audit. The inclusion criteria 
involved adult patients on any regular fixed doses 
of insulin.  Patients who were on an intravenous 
insulin infusion were excluded. Each participant 
involved with data collection would review their 
allocated wards to include any newly admitted 
patients. The 1st audit was carried out over a 4-week 
period in 2013. The re-audit was carried out over a 
12-week period in 2017 following educational
sessions to both doctors and nurses.
The audit was carried out by all the authors of 
this manuscript together with the doctors mentioned 
in the acknowledgement section.  A proforma was 
drawn up by one of the authors and this was then 
reviewed and endorsed by the supervising 
consultant. In addition to this, all doctors involved 
with data collection were asked to attend a briefing 
on the proforma to ensure conformity in the data 
collection process. The briefing was carried out by 
the most senior author participating in the audit. 
Educational sessions were given by the 
corresponding authors together with a diabetes 
specialist nurse after the results of the first audit 
were issued. These were one hourly one-time 
sessions, where all doctors and nurses working at 
Mater Dei hospital were invited to attend via emails 
from the respective associations. A new treatment  
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chart, with space available to write any 
important instructions for any prescribed drug, had 
also been issued prior to the re-audit. The same 
proforma was used for both audits.  
The proforma consisted of six parts: the first 
section included demographic data of each patient 
recruited, including age, sex, type of diabetes and 
reason for admission. The second part was 
concerned with treatment, specifically the type of 
insulin the patient was on.  In the third section 
details of insulin and supplementary Actrapid® 
prescription, including a correctly filled algorithm 
available in the patients’ files, was audited. Correct 
insulin prescription involved writing insulin and 
dose correctly and legibly, ‘Units’ in full and clear 
instructions on when to administer insulin in 
relation to meals. This was in turn followed up by 
auditing whether BGM and insulin administration, 
including supplementary Actrapid®, was carried 
out in relation to meals according to the local 
protocol. Any inappropriate insulin omission was 
recorded. Insulin omission was taken as 
inappropriate if omitted following correction of 
hypoglycaemic episode12 or if not given despite the 
patient having a BGM >4mmol/L and not nil by 
mouth in both cases. The last section included 
details about any complications, mainly 
hypoglycaemia (BGM <4mmol/L)12 or 
hyperglycaemia (BGM persistently >10mmol/L),13 
that might have arisen from errors of insulin 
prescription and administration.  
The results were tabulated using an Excel® 
spreadsheet and expressed as absolute numbers and 
percentage values with the help of Microsoft 
Excel®. When comparing the results between the 
two audits the z-test was used. The International 
Business Machines Corporation Statistical Package 
for the Social Sciences programme was utilized for 
this purpose. A p-value of <0.05 was used to define 
statistical significance.   
Permission from all consultants who were 
directly responsible for the management of these 
patients was obtained as well as approval from the 
data protection officer in order to access the 
patients’ files. Ethics approval was not sought as at 
no point did any of the participants have any form 
of contact with the recruited patients. 
Results 
One hundred and five insulin-treated patients 
with diabetes admitted to 19 medical wards at 
Mater Dei Hospital were recruited during the 
original audit, while 150 patients were recruited 
during re-audit. Demographic data and treatment 
with different insulin regimes for both audit 
samples are shown in table 1 and figure 1 
respectively.  
Table 1: Demographic characteristics and frequency of patients in 1st audit and re-audit 
Demographic 
characteristics
1st Audit 
(N = 105) 
Re-audit 
(N = 150) 
P a
Age, mean ± SD 69 ± 13.7 71.8 ± 12.5 0.15 
Gender 0.869 
No. female 55 77
% female 52.4 51.3 
Type of Diabetes 
Mellitus
0.146 
No. T1DM 10 7
% T1DM 9.5 4.7 
No. T2DM 95 143
% T2DM 90.5 95.3 
a z-test 
SD- standard deviation; No- Number; %- percentage; T1DM- type 1 diabetes; T2DM- type 2 diabetes. 
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Figure 1: Different insulin regimes in 1st audit and re-audit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Insulin prescription errors 
A satisfactory result in writing the insulin 
name correctly and legibly was present in both 
audits, while an improvement in dose legibility was 
noted in the re-audit (see table 2). A significant 
improvement in writing ‘Units’ in full rather than 
abbreviated ‘U’ was recorded compared to the 
original audit (23.8% in 2013 to 41.3% in 2017, 
p=0.002). Moreover, supplementary Actrapid® was 
prescribed more often (74.8% in 2013 to 85.5% in 
2017, p=0.002). However, no improvement in the 
prescription of insulin or supplementary Actrapid® 
in relation to meals was observed despite education 
and the launch of a new treatment chart in 2016. 
 
BGM and insulin administration 
BGM was carried out in all patients except for 
one patient in the re-audit. Capillary blood glucose 
was monitored at the correct time in relation to 
meals in 39% of patients during the initial audit 
(Table 3). This improved to 61.3% in the re-audit 
(p=<0.001).  
Time of administration of insulin was charted 
in 97.3% in the re-audit, which is a significant 
increase from 55.2% noted in the original audit 
(p=<0.001). Correct insulin administration in 
relation to meals was observed to be more in 
accordance with the local guideline in the re-audit 
compared to the original audit (71.2% vs 31.0% 
respectively, p=<0.001). A poor compliance to our 
local protocol with regards to the administration of 
supplementary Actrapid® (where prescribed) in 
relation to meals and when BGM was more than 
8mmol/L was noted in both audits. However, when 
given, a significant improvement in the 
documentation of the timing and the dose 
administered was observed in the re-audit 
(p=<0.001). Moreover, it was more often signed for 
compared to the first audit (Table 3).  
 
Insulin Omission and Complications 
Insulin was inappropriately omitted more 
often in the re-audit (3.8% to 10%, p = 0.044). No 
documented reason for insulin omission was present 
in all cases during the first audit and in 46.7% of 
cases in the re-audit. Inappropriate omission after 
treated hypoglycaemia or in the presence of normal 
but lowish BGM (between 4 and 5mmol/L) was 
present in 53.3% of cases in the second audit.  
A greater number of complications secondary 
to errors in insulin prescription/administration were 
recorded in the re-audit (3.8% 2013 compared to 
38.6% in 2017, p=<0.001). Observed complications 
are shown in figure 2.  
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Table 2: Absolute numbers and percentage values of insulin prescription errors in the 
1st audit and in the re-audit 
a z-test
* Patients on Novorapid® excluded
No – absolute numbers
Insulin prescription 
errors 
1st Audit Re-audit 
P a 
N No (%) N No (%) 
Written correctly 105 100 (95.2%) 150 134 (89.3%) 0.071 
Insulin name legible 105 96 (91.4%) 150 138 (92.0%) 0.871 
Doses legible 105 86 (81.9%) 150 138 (92.0%) 0.021 
‘Units’ Written in full 105 25 (23.8%) 150 62 (41.3%) 0.002 
When 
‘Units’ 
not 
written in 
full 
‘U’ written 
like a zero 
80 2 (2.5%) 88 4 (4.6%) 0.469 
‘Units’ not 
written at all 
80 5 (6.3%) 88 11 (12.5%) 0.160 
Insulin prescribed in 
relation to meals 
105 10 (9.5%) 150 11 (7.3%) 0.539 
Supplementary 
Actrapid® prescribed*
103 77 (74.8%) 145 124 (85.5%) 0.038 
Supplementary 
Actrapid® prescribed in 
relation to meals (when 
prescribed) 
77 9 (11.7%) 124 9 (7.3%) 0.307 
Supplementary 
Actrapid® algorithm 
present in file* 
103 59 (57.3%) 145 99 (68.3%) 0.077 
Correctly filled 
supplementary Actrapid® 
algorithm (if present in 
file) 
59 38 (64.4%) 99 69 (69.7%) 0.495 
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Table 3: BGM and administration of insulin in 1st audit and re-audit 
a z-test 
No – absolute numbers; BGM- blood glucose monitoring 
*Where supplementary Actrapid® was prescribed and/or given; patients on Novorapid® excluded.
BGM and insulin 
administration 
1st Audit Re-audit 
P a 
N No (%) N No (%) 
BGM monitoring 105 105 (100%) 150 149 (99.3%) 0.316 
Correct time of BGM 
monitoring 
105 41 (39.1%) 150 92 (61.3%) <0.001 
Less frequent BGM 
monitoring than 
recommended 
64 5 (7.8%) 58 7 (12.1%) 0.434 
More frequent BGM 
monitoring than 
recommended 
64 18 (28.1%) 58 39 (67.2%) <0.001 
Administration of regular 
insulin signed on treatment 
chart 
105 100 (95.2%) 150 142 (94.7%) 0.837 
Time of administration of 
fixed dose charted 
105 58 (55.2%) 150 146 (97.3%) <0.001 
Correct administration of 
insulin in relation to meals 
58 18 (31.0%) 146 104 (71.2%) <0.001 
Supplementary Actrapid® 
administered as per 
algorithm* 
97 26 (26.8%) 103 30 (29.1%) 0.714 
Administered 
supplementary Actrapid® 
signed and dose given 
documented* 
97 54 (55.7%) 84 73 (86.9%) <0.001 
Time of administered 
supplementary Actrapid® 
documented* 
97 52 (53.6%) 84 75 (89.3%) <0.001 
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Figure 2: Type and frequency of complications secondary to errors in insulin prescription/administration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Educational sessions to doctors were effective 
in improving some aspects of insulin prescription, 
as prescribed insulin doses were more legible, 
insulin ‘Units’ were more frequently written in full, 
while supplementary Actrapid® was prescribed 
more often in patients not taking short-acting 
insulin analogues. Although, no improvement was 
noted with regards to writing insulin names 
correctly and legibly, this was done appropriately in 
the majority of cases. Educational sessions to nurses 
also led to a significant improvement in the timing 
of BGM and insulin administration in relation to 
meals and in the documentation of the time of any 
administered insulin. 
Although more complications were 
documented in the re-audit, it is possible that blood 
glucose charts were scrutinized more closely in the 
re-audit, as data collection was carried out mainly 
by diabetologists/diabetes trainees, while in the first 
audit data collection was primarily carried out by 
foundation doctors and basic specialist trainees. The 
majority of complications occurred secondary to 
non-adherence with our local supplementary 
Actrapid® algorithm, resulting in persistently high 
BGM as supplementary Actrapid® was not always 
given when blood glucose was more than 8mmol/L 
pre-meals and at bedtime. 
 
Unfortunately, no improvement was observed in 
the prescription of insulin including supplementary 
Actrapid® at the correct time in relation to meals 
despite the introduction of a new treatment chart, 
which included extra space dedicated for the 
documentation of any important instructions 
regarding the prescribed drug. This could be due to 
the heavy work-load doctors have to endure during 
duty hours. In order to ensure accurate prescription 
of insulin, including clear instructions of when to 
administer insulin and supplementary Actrapid® in 
relation to meals, we propose the drafting of a 
prescription chart devoted for insulin therapy, 
incorporating a blood glucose and ketone 
monitoring chart. The appropriate time when to 
check blood glucose in relation to meals will be 
written clearly on the treatment chart and will 
provide a space to prescribe hypoglycaemia 
medications. The treatment chart will also include a 
space to provide clear instructions with regards to 
the timing of insulin administration. Such treatment 
chart, including hypo- and hyperglycaemia trouble-
shooting guidelines, was found to significantly 
improve compliance with evidence-based practice, 
insulin administration timing, hypoglycaemia 
control and provided a means to educate non-
specialist staff.14  
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Inappropriate omission of fixed insulin doses 
was observed more often in the re-audit, with the 
majority of cases being due to a blood glucose of 
between 4-5mmol/L or hypoglycaemia. Further 
educational sessions to both nurses and doctors will 
be required to stress the importance of not omitting 
insulin in cases of hypoglycaemia. In such cases 
insulin doses should be reviewed, as insulin 
omission can result in rebound hyperglycaemia and 
diabetic ketoacidosis.12   
Patients who are experienced and competent to 
manage their diabetes should be involved in 
decisions regarding their diabetes management.4 
Giving such patients the choice to self-monitor and 
self-manage their own diabetes and insulin may 
result in reduction of errors involving insulin 
administration including type and dose as well as 
timing in relation to meals, all of which can lead to 
better glucose control and reduced hospital stays. 
Therefore, implementing a policy for diabetes self-
management at Mater Dei hospital, while allowing 
flexibility for changing clinical situations, may 
further help with reduction of insulin prescription 
and administration errors and resultant patient harm. 
The diabetes specialist team should be immediately 
involved if further education on diabetes self-
management is required or if blood glucose is 
uncontrolled.15 
Another strategy which was found to be 
successful, is the implementation of a multifaceted 
multidisciplinary prevention team, which would 
monitor insulin prescription, dispensing and 
administration. This strategy also involved 
authentication of any short-acting insulin orders 
above 25 units and other insulins above 50 units by 
different individuals, together with continued staff 
education on product-labelling warnings and on the 
importance to adhere to protocols.16  In another 
study, the use of a diabetes specialist nurse 
prescriber, who reviewed prescription of insulin and 
oral hypoglycaemic agents (OHA), provided 
education to patients, medical and nursing staff 
when needed, continued to review insulin and OHA 
regimes and prescribed if medical staff were 
unavailable in emergency situations or if delay in 
prescribing will harm the patient, significantly 
reduced the number of insulin and OHA medication 
errors and reduced hospital stay.17 Both 
aforementioned strategies may therefore help to re-
enforce adherence to current local supplementary 
Actrapid® algorithm, so that supplementary 
Actrapid® can be administered when needed and at 
the correct time, thus avoiding both hypo- and 
hyperglycaemia. Computer-based clinical decision 
support systems might similarly help to further 
improve inpatient diabetes care.18  
The results of our audit could have been 
constrained by three major limitations. Although we 
asked nursing staff in each ward the times when the 
main meals were distributed to patients, we could 
never know for sure whether the recruited patients 
ate their meals or had their food distributed at that 
exact time. Therefore, matching the documented 
time of any administered insulin with meal times 
might have been inaccurate. Moreover, any 
incorrect documentation of the time when blood 
glucose was monitored or when insulin was 
administered would have impacted our results. 
Lastly, there was no way of knowing for sure 
whether the correct type and dose of insulin was 
administered. Such limitations may be overcome by 
carrying out a prospective study, where insulin 
administration and its timing in relation to meals 
will be directly observed by the researcher.  
In conclusion, although educational sessions led 
to some improvement in insulin prescription and 
administration, further work needs to be done to 
ensure patient safety in hospital and to avoid 
inadvertent patient harm secondary to errors in 
insulin prescription and administration.  
Summary Box 
What is known: 
1. Insulin is a high-alert medication with a narrow
therapeutic index.
2. Incorrect insulin prescription and
administration can result in patient harm and
medication error related mortality.
3. Errors in insulin prescription and
administration can be the result of impaired
communication, illegible handwriting, heavy
work-loads and unawareness of the possible
complications related to incorrect insulin
prescription and administration.
New findings: 
1. Education is effective in improving some
aspects of insulin prescription and
administration.
2. Lack of adherence to our local supplementary
Actrapid® algorithm and inappropriate insulin
omission resulted in capillary blood glucose
readings to remain persistently high and in
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rebound hyperglycaemia respectively. 
3. The introduction of a new treatment chart with 
space dedicated for documentation of any 
important instructions related to the prescribed 
drug did not improve insulin prescription in 
relation to meals.  
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